Breaking News Instant updates and real-time market news.

CNTTF

CannTrust Holdings

$0.00

(0.00%)

, CVSI

CV Sciences

$0.00

(0.00%)

11:34
08/29/19
08/29
11:34
08/29/19
11:34

Illinois to allow medical cannabis dispensary to obtain adult dispensing license

The Illinois Department of Financial and Professional Regulation announced the first "Same Site" adult use cannabis licenses, which will allow an existing medical cannabis dispensary to obtain an adult use dispensing license. The license will permit the dispensary to begin adult use cannabis sales at that location starting January 1, 2020, provided the dispensary complies with local zoning rules or other local laws. In addition to opening adult use dispensaries at the same site of their medical cannabis dispensaries, existing medical cannabis dispensaries are permitted under the law to open a second site for adult use sales at a different location, the agency said. Starting January 1, 2020, the law permits Illinois residents to legally possess up to 30 grams of cannabis flower and up to five grams of cannabis concentrate. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY), Trulieve Cannabis (TCNNF) and Zynerba (ZYNE). Reference Link

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

TLRY

Tilray

$27.20

0.02 (0.07%)

CRON

Cronos Group

$11.22

0.07 (0.63%)

ZYNE

Zynerba

$11.07

0.54 (5.13%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.03

(0.00%)

CGC

Canopy Growth

$24.59

0.38 (1.57%)

ACB

Aurora Cannabis

$5.61

0.04 (0.72%)

APHA

Aphria

$6.37

0.15 (2.41%)

TCNNF

Trulieve Cannabis

$0.00

(0.00%)

  • 19

    Sep

CNTTF CannTrust Holdings
$0.00

(0.00%)

02/25/19
JEFF
02/25/19
INITIATION
JEFF
Buy
CannTrust Holdings initiated with a Buy at Jefferies
Jefferies analyst Owen Bennett initiated coverage of nine cannabis stocks, stating that his base-case "conservative" assumption is that the cannabis industry can grow in size to over $50B by 2029 from $17B in 2019. He started CannTrust Holdings with a Buy rating and C$15 price target, citing his view that it has "one of the strongest medical businesses in Canada" and "has slipped under the radar," maybe due to its non-U.S. listing.
02/25/19
02/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Antares Pharma (ATRS) initiated with an Outperform at Cowen. 2. New Fortress Energy (NFE) initiated with a Buy at Citi and Stifel, an Overweight at Morgan Stanley, an Equal Weight at Barclays and an Oupterform at JMP Securities and Evercore ISI. 3. Aurora Cannabis (ACB), CannTrust Holdings (CNTTF), Flowr (FLWPF), Organigram (OGRMF) and The Green Organic Dutchman (TGODF) initiated with a Buy at Jefferies, Canopy Growth (CGC) and Emerald Health Therapeutics (EMHTF) initiated with a Hold, Cronos Group (CRON) and HEXO (HEXO) initiated with an Underperform. 4. Pulse Biosciences (PLSE) initiated with a Buy at H.C. Wainwright. 5. Beacon Roofing (BECN) initiated with a Neutral at Buckingham, while the firm initiated BMC Stock Holdings (BMCH) and TopBuild (BLD) with a Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/19
COWN
03/14/19
NO CHANGE
COWN
Narrow U.S. cannabis bills have better prospects than broad ones, says Cowen
Cowen analyst Jaret Seiberg said it is hard for him to see a scenario in the 116th Congress in which Senate Majority Leader Mitch McConnell holds a vote on legislation to fully legalize cannabis, as too many senators see no political upside for McConnell to schedule such a vote. Given this view, Seiberg believes that prospects are better for narrower bills that could get attached to spending packages and other measures than for broader bills that would legalize recreational use. Of the narrower bills introduced in the U.S. so far, Seiberg believes the SAFE Act on cannabis banking has the best shot before the 2020 election. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
06/10/19
PIPR
06/10/19
NO CHANGE
PIPR
Cannabis regulation could become top 2020 election issue, says Piper Jaffray
After Washington D.C. lobbyist Michael Esposito, who also works closely with President Trump's administration, spoke at his firm's conference, Piper Jaffray analyst Michael Lavery believes cannabis regulation could become a top 2020 election issue. By supporting cannabis, Trump may be able to incrementally broaden his appeal with swing voters without alienating his base, Esposito tells investors in a research note. Though Trump has indicated his willingness to support the STATES Act, his enthusiasm could depend on whether or not Elizabeth Warren, author of the bill, is his opponent, adds the analyst in a note titled "Handicapping US Legalization Outlook: Politics Are Complicated." And while Senate Majority Leader Mitch McConnell is a roadblock for legislation in the Senate, Trump could use executive orders between now and the election to show support for the industry, potentially relating to cannabis banking or medical research, says Lavery. The analyst has Overweight ratings on both Canopy Growth (CGC) and Tilray (TLRY). Other names in the space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Zynerba (ZYNE).
CVSI CV Sciences
$0.00

(0.00%)

08/12/19
PIPR
08/12/19
INITIATION
Target $5
PIPR
Overweight
CV Sciences initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery started CV Sciences with an Overweight rating and $5 price target.
08/13/19
PIPR
08/13/19
INITIATION
Target $5
PIPR
Overweight
CV Sciences initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery last night initiated coverage of CV Sciences with an Overweight rating and $5 price target. The analyst says CV Sciences is the second largest public U.S. CBD company by revenues, and he expects its distribution expansion to drive near-term sales growth. He considers science and regulation to be a core competency for CV Sciences, and also believes that clarity on FDA regulation for other products is a "looming positive catalyst." Lavery believes the U.S. CBD market could be an $8B-$15B market in five years.
05/16/19
05/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Jefferies starts 'underappreciated' Par Technology (PAR) with Buy rating. 2. Ichor Holdings (ICHR) initiated with a Buy at B. Riley FBR. 3. T2 Biosystems (TTOO) initiated with a Buy at Alliance Global Partners. 4. CV Sciences (CVSI) initiated with a Buy at Roth Capital. 5. Hillenbrand (HI) initiated with a Buy at Buckingham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TLRY Tilray
$27.20

0.02 (0.07%)

08/14/19
STFL
08/14/19
NO CHANGE
Target $38
STFL
Hold
Stifel keeps Hold rating, $38 price target on Tilray after Q2 report
Stifel analyst W. Andrew Carter said Tilray's Q2 revenue performance exceeded his expectations and he believes the company's report underscores the cannabis industry's preeminent theme - namely, robust revenue growth opportunity bumping up against a high degree of investment needed to capitalize on a "once-in-a-lifetime" opportunity. Following the report, he increased his FY19 gross revenue estimate to $171M, but lowered his EBITDA estimates to conform more closely to the company's guidance. Carter keeps a Hold rating and $38 price target on Tilray shares, but said he thinks the stock could come under pressure as he believes investors may focus on the wider than expected EBITDA losses.
08/14/19
BNCH
08/14/19
NO CHANGE
Target $80
BNCH
Buy
Tilray price target lowered to $80 from $200 at Benchmark
Benchmark analyst Mike Hickey lowered his price target on Tilray shares to $80 from $200 after the company reported "mixed" Q2 results. The company's "near term profitability aspirations have been abandoned" as Tilray seeks to take additional market share, said Hickey, who remains cautious on the Canadian regulatory regime and expects on-going supply and distribution constraints. However, he keeps a Buy rating on Tilray shares.
08/15/19
VERF
08/15/19
NO CHANGE
Target $4
VERF
Sell
Vertical Group sees 90% downside in Tilray, says 'back up truck' to short
It is time to "back up the truck" and short shares of Tilray, Vertical Group analyst Gordon Johnson tells investors in a research note. The analyst introduced a year-end 2020 price target of $4, which implies around 90% downside to Tilray's closing price Wednesday of $39.04. The company's top shareholder, Privateer, is set to unload its 72% position over the course of this year and next, Johnson points out. Further, the analyst calls Tilray's Q2 results "horrific." On top of that, the company, which only has two-to-three quarters of cash left, admitted its results are slated to get worse, adds Johnson. The analyst says that in his years covering stocks, he's rarely seen such a richly valued company.
08/23/19
COWN
08/23/19
NO CHANGE
Target $150
COWN
Outperform
Tilray top-line progression keeps us constructive, says Cowen
Cowen analyst Vivien Azer met with Tilray management following impressive Q2 results. The analyst admitted the company's cash use is high but said the company is making investments to reach its goal if becoming a global leader with cannabis. He believes the company could look to raise capital in the back half of 2020 but is comforted by management's expectations for Canada profitability sometime in the quarter or so. Azer reiterated her Outperform rating and $!50 price target on Tilray shares.
CRON Cronos Group
$11.22

0.07 (0.63%)

08/09/19
ADAM
08/09/19
UPGRADE
ADAM
Hold
Cronos Group upgraded to Hold from Sell at Canaccord
Canaccord Genuity analyst Matt Bottomley upgraded Cronos Group to Hold from Sell and raised his price target for the shares to C$17 from C$16.
08/13/19
PIPR
08/13/19
INITIATION
Target $18
PIPR
Overweight
Piper sees 'strong' sales growth for Cronos, starts with Overweight rating
Piper Jaffray analyst Michael Lavery last night initiated coverage of Cronos Group (CRON) with an Overweight rating and $18 price target. The analyst expects "strong" sales growth from Cronos, driven by "sustainable category momentum." The company's partnership with Altria (MO) provides important capital and access into 230,000 US retail outlets, as well as regulatory and vapor product expertise, Lavery tells investors in a research note. He expects Cronos to have "modest" near-term revenues from Canadian cannabis production, but believes it has "significant" potential growth opportunities with CBD products in the U.S.
08/13/19
08/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Simply Good Foods (SMPl) initiated with an Outperform at Bernstein. 2. AMD (AMD) and Intel (INTC) initiated with a Hold at Loop Capital. 3. Cronos Group (CRON) initiated with an Overweight at Piper Jaffray. 4. Medallia (MDLA) initiated with an Outperform at William Blair, Wells Fargo, and Oppenheimer, a Buy at Roth Capital, Needham, and BofA/Merrill, as well as a Neutral at Credit Suisse and Citi. 5. Sempra Energy (SRE) initiated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/12/19
PIPR
08/12/19
INITIATION
Target $18
PIPR
Overweight
Cronos Group initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery started Cronos Group with an Overweight rating and $18 price target.
ZYNE Zynerba
$11.07

0.54 (5.13%)

05/31/19
CANT
05/31/19
NO CHANGE
Target $22
CANT
Overweight
Zynerba price target raised to $22 from $12 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Zynerba Pharmaceuticals to $22 from $12 citing his due diligence on Fragile X and the anecdotal use of CBD to alleviate symptoms for this and other pediatric orphan neurodevelopmental disorders. The analyst says he's also seen broadening interest in the medical cannabis space with the emergence of exchange traded funds possibly driving demand for the shares. Duncan reiterates an Overweight rating on Zynerba.
05/08/19
05/08/19
NO CHANGE

Zynerba reports Q1 EPS (47c), consensus (49c)
05/31/19
HCWC
05/31/19
NO CHANGE
Target $23
HCWC
Buy
Zynerba remains 'potentially dramatically undervalued,' says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says that even with the stock up 324% year-to-date, shares of Zynerba Pharmaceuticals remain "potentially dramatically undervalued." The analyst continues to entirely value the company on the opportunity in Fragile X Syndrome, and he expects Zynerba to soon announce CONNECT-FX Phase 3 enrollment completion which would put the company on track for transformative topline data in Q4. He projects peak U.S. sales of $700M and keeps a Buy rating on the shares with a $23 price target.
CANN General Cannabis
$0.00

(0.00%)

11/07/18
ADAM
11/07/18
NO CHANGE
ADAM
Midterms broadly positive for U.S. cannabis industry, says Canaccord
Canaccord analyst Bobby Burleson says that as expected, yesterday's midterms delivered several wins for the U.S. cannabis industry, including the passage of three state ballot measures on legalization, key gubernatorial victories by pro-cannabis candidates, and the retaking of the House by Democrats. The analyst views these results as broadly positive for the U.S. cannabis industry. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
02/14/19
COWN
02/14/19
NO CHANGE
COWN
SAFE Act should pass House, Senate path less clear, says Cowen
After the House Financial Services financial institutions subcommittee held a hearing on legislation that would permit banks to provide service to cannabis companies that are in compliance with state law, Cowen analyst Jaret Seiberg said he believes the hearing went well enough for the SAFE Act to pass the committee and the full House later this year. However, the path forward in the Senate is "less clear," said Seiberg. The analyst, whose base call remains that the House passes the SAFE Act and other cannabis laws and that the Senate then pushes through a package before the end of the 116th Congress, expects "positive news by the end of 2020 for cannabis companies," he tells investors. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
IGC India Globalization Capital
$1.03

(0.00%)

CGC Canopy Growth
$24.59

0.38 (1.57%)

08/26/19
GHSC
08/26/19
UPGRADE
Target $31
GHSC
Buy
Seaport Global upgrades Canopy Growth to Buy with $31 price target
Seaport Global analyst Brett Hundley upgraded Canopy Growth to Buy from Neutral with a $31 price target. The stock closed Friday down 24c to $24.89. Canopy shares have now "round-tripped themselves" year-to-date, and are down 7.4% compared to a 13.6% increase in the S&P 500, Hundley tells investors in a research note. Although the analyst moderated his sales and margin expectations, he believes the new bar is "increasingly achievable." Further, the beta for cannabis generally, and Canopy specifically, "needs to improve ahead," contends the analyst. He thinks the North American cannabis industry can "actually help to provide some safety for investors" and finds Canopy Growth shares attractive.
08/16/19
BNCH
08/16/19
NO CHANGE
BNCH
Buy
Canopy Growth price target lowered to C$60 from C$100 at Benchmark
Benchmark analyst Mike Hickey noted that Canopy Growth reported "disappointing" Q1 sales and continued to struggle with profitability and he suspects investors are now favoring disciplined growth and a path to profitability as the global cannabis market has not been achieving the presumed near-term growth. He noted, though, that Canopy realized an "enormous" harvest in Q1, which leads Hickey to anticipate near-term performance trends will improve. The analyst, who also points to Canadian legalization of new cannabis product categories and the U.S. CBD market as upcoming catalysts, keeps a Buy rating on Canopy shares but lowered his price target on the stock to C$60 from C$100.
08/26/19
GHSC
08/26/19
UPGRADE
Target $31
GHSC
Buy
Canopy Growth upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Brett Hundley upgraded Canopy Growth to Buy from Neutral with a $31 price target.
08/26/19
08/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dish (DISH) double upgraded to Strong Buy from Market Perform at Raymond James with analyst Richard Prentiss saying following the recent pullback on investor concerns about the shift from a spectrum bank to a wireless operator, now is the "opportune time" to buy shares of Dish. 2. Lyft (LYFT) upgraded to Buy from Neutral at Guggenheim with analyst Jake Fuller saying improving U.S. ride hail competitive dynamics and Lyft's "surprising leverage to that trend" should allow the company to reach EBITDA positive in 2021 versus prior expectations of 2023. 3. Canopy Growth (CGC) upgraded to Buy from Neutral at Seaport Global with analyst Brett Hundley saying Canopy shares have now "round-tripped themselves" year-to-date, and are down 7.4% compared to a 13.6% increase in the S&P 500. 4. Copel (ELP) upgraded to Overweight from Neutral at JPMorgan with analyst Fernando Abdalla saying the company's cash flows are expanding in 2019 and its leverage coming down with the start-up of important greenfield projects. 5. VICI Properties (VICI) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Thomas Allen saying the stock has underperformed since the merger announcement between Eldorado Resorts (ERI) and Caesars Entertainment (CZR) on concerns that the deal will result in greater tenant risk, but he believes that it makes Caesar's rent "better covered by free cash flows" in a recession and that the underperformance is overdone. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ACB Aurora Cannabis
$5.61

0.04 (0.72%)

07/17/19
LTCO
07/17/19
INITIATION
Target $9
LTCO
Buy
Aurora Cannabis initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Glenn Mattson started Aurora Cannabis with a Buy rating and $9 price target. Within the cannabis space, the analyst favors Canadian companies who are focused on long-term value creation and gaining market share as well as those with a well-defined plan for potentially entering the U.S. market. He initiated coverage on the cannabis space with a "bullish long-term outlook." Aurora is one of the most aggressive capacity expansion plays in the cannabis universe, Mattson tells investors in a research note. While many companies are adding capacity with a "cautious eye toward a potential oversupply situation," Aurora is taking the view that cannabis production has consistently failed to keep up with demand in the small Canadian market, he explains. Further, Mattson believes Aurora has a well-defined international strategy.
07/18/19
BOFA
07/18/19
DOWNGRADE
Target $8
BOFA
Neutral
Aurora Cannabis downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Chris Carey downgraded Aurora Cannabis to Neutral from Buy and cut its price target to $8 from $10. Carey said is one of the best operators in the cannabis sector, but is "burning cash, and will likely be cash negative by Q1 2020, especially if a large convertible debenture due Q1 stays out of the money.
08/12/19
PIPR
08/12/19
INITIATION
Target $7
PIPR
Neutral
Aurora Cannabis initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery started Aurora Cannabis with a Neutral rating and $7 price target.
08/13/19
PIPR
08/13/19
INITIATION
Target $7
PIPR
Neutral
Aurora Cannabis initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery last night initiated coverage of Aurora Cannabis with a Neutral rating and $7 price target. Aurora has a premium valuation relative to peers but less visibility on key growth opportunities, Lavery tells investors in a research note. The company has leading scale in Canada, but oversupply looks likely in 2020, says the analyst.
APHA Aphria
$6.37

0.15 (2.41%)

07/26/19
CIBC
07/26/19
DOWNGRADE
CIBC
Underperformer
Aphria downgraded to Underperformer from Neutral at CIBC
CIBC analyst John Zamparo downgraded Aphria to Underperformer from Neutral and lowered his price target for the shares to $6.50 from $12. The stock closed Thursday down 23c to $5.84. The analyst cites concerns about "aggressive" Street estimates, potential asset impairment, a "leadership void and less robust supply contracts" for the downgrade. While Aphria likely captures a high-single-digit market share, and last month's partnership with PAX Era was a "meaningful win," the stock carries more risk than reward at current levels, Zamparo tells investors in a research note. The analyst believes consensus estimates need to come down to reflect slower industry growth than previously contemplated. He thinks this will pressure the stock.
05/24/19
JEFF
05/24/19
INITIATION
JEFF
Buy
Jefferies starts Aphria at Buy, says valuation 'not reflective of reality'
Jefferies analyst Owen Bennett initiated coverage of Aphria (APHA) with a Buy rating and C$15 price target. The stock closed yesterday down 33c to $6.41. The analyst says the company scores highly on his "strategic scorecard," or third overall behind only Canopy Growth (CGC) and Aurora Cannabis (ACB). Despite a "strong global outlook," Aphria's valuation is the cheapest across the space, with allegations around inflated assets/insider deals weighing on the shares, Bennett tells investors in a research note. The analyst expects a "significant re-rating" in the shares with "these issues now seemingly cleared up." He points out that the company's questionable relationships have been severed and a special committee review found assets had not been falsely inflated. Bennett believes Aphria continues to execute and that its valuation is "not reflective of reality."
05/24/19
05/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Perform at Oppenheimer. 2. CannTrust (CTST) initiated with a Buy at BofA/Merrill. 3. Inseego (INSG) initiated with an Outperform at Cowen. 4. Falcon Minerals (FLMN) initiated with an Outperform at Baird. 5. Aphria (APHA) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TCNNF Trulieve Cannabis
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

06:40
01/20/20
01/20
06:40
01/20/20
06:40
General news
FX Action: USD-JPY has gone into narrow-range mode »

FX Action: USD-JPY has…

AMRC

Ameresco

$19.78

-0.1 (-0.50%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
Ameresco management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 21

    Jan

  • 22

    Jan

HRB

H&R Block

$24.48

-0.48 (-1.92%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
H&R Block management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 21

    Jan

  • 22

    Jan

MSM

MSC Industrial

$76.89

-1.58 (-2.01%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
MSC Industrial management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 29

    Jan

03:30
01/20/20
01/20
03:30
01/20/20
03:30
General news
FX Action: USD-CAD ebbed fractionally lower »

FX Action: USD-CAD ebbed…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
FX Update: The dollar has seen modest weakness »

FX Update: The dollar has…

FB

Facebook

$222.01

0.23 (0.10%)

16:50
01/19/20
01/19
16:50
01/19/20
16:50
Periodicals
Facebook blames technical error for vulgar translation, Reuters reports »

Facebook blamed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:43
01/19/20
01/19
16:43
01/19/20
16:43
Periodicals
China to increase U.S. imports according to 'market principles,' Reuters reports »

China will negotiate with…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$510.34

-3.065 (-0.60%)

16:33
01/19/20
01/19
16:33
01/19/20
16:33
Periodicals
Tesla closer to opening first European factory with property deal, Reuters says »

Tesla has agreed to buy a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

JPM

JPMorgan

$138.15

0.89 (0.65%)

, BNPQY

BNP Paribas

$0.00

(0.00%)

16:28
01/19/20
01/19
16:28
01/19/20
16:28
Periodicals
JPMorgan to acquire former BNP building in Paris, Bloomberg reports »

JPMorgan (JPM) is buying…

JPM

JPMorgan

$138.15

0.89 (0.65%)

BNPQY

BNP Paribas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 25

    Feb

  • 14

    Apr

BAC

Bank of America

$34.70

-0.03 (-0.09%)

16:25
01/19/20
01/19
16:25
01/19/20
16:25
Periodicals
CEO tells FT Bank of America aims to 'double' slice of U.S. retail business »

Bank of America can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 15

    Apr

CEL

Cellcom Israel

$3.18

(0.00%)

16:16
01/19/20
01/19
16:16
01/19/20
16:16
Hot Stocks
Cellcom Israel announces CTO resignation »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRCA

Verrica Pharmaceuticals

$15.94

0.21 (1.34%)

16:12
01/19/20
01/19
16:12
01/19/20
16:12
Hot Stocks
Verrica announces presentation of data from Phase 3 CAMP trials of VP-102 »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

SO

Southern Company

$67.25

1.08 (1.63%)

, XEL

Xcel Energy

$65.38

0.34 (0.52%)

16:08
01/19/20
01/19
16:08
01/19/20
16:08
Hot Stocks
Southern Power closes sale of Mankato Energy Center to Xcel Energy »

Southern Power, a…

SO

Southern Company

$67.25

1.08 (1.63%)

XEL

Xcel Energy

$65.38

0.34 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

LIZI

Lizhi

$11.72

(0.00%)

, DNK

Phoenix Tree

$13.50

(0.00%)

09:10
01/19/20
01/19
09:10
01/19/20
09:10
On The Fly
Opening Day: China's Lizhi, Phoenix Tree flat in trading debut »

Lizhi (LIZI), one of…

LIZI

Lizhi

$11.72

(0.00%)

DNK

Phoenix Tree

$13.50

(0.00%)

VEL

Velocity Financial

$13.58

(0.00%)

IMAB

I-MAB

$12.90

(0.00%)

BSBK

Bogota Financial

$11.70

0.195 (1.70%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.